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Cancer cell linesTreatment of cancer patients with low molecular weight heparin (LMWH) appears to have beneﬁcial effects. In
this study, the inﬂuence of low molecular weight heparin (LMWH) on tissue factor (TF) expression and activity
in ﬁve cell lines from various tissues was analysed and explored. Incubation of cells with LMWH (0–2000 μg/ml)
resulted in the downregulation of TF mRNA expression which was both LMWH concentration-dependent and
time-dependent. Downregulation of TF was also measured as decreased cellular TF antigen and activity. Consis-
tently, incubation of cells with LMWH suppressed the nuclear localisation and the transcriptional activity of
NFκB. Decreased TF mRNA was largely achievable by incubating the cells with an NFκB inhibitor alone whilst
incubation with betulinic acid to activate NFκB reversed the inhibitory inﬂuence of LMWH. Cells were also incu-
bated with a range of concentrations of EGF (0–10 ng/ml), bFGF (0–20 ng/ml) or VEGF (0–4 ng/ml) in the pres-
ence or absence of LMWH (200 μg/ml) for 24 h and TF antigen measured. Inclusion of LMWH reduced TF
expression in response to EGF, bFGF or VEGF but TF expression was partially restored by increasing concentra-
tions of the growth factors.We conclude that LMWHdownregulates TF expression in vitro through amechanism
that involves interference with the function of growth factors which in turn is mediated through the downregu-
lation of the transcriptional activity of NFκB. This mechanismmay also explain some of the beneﬁcial inﬂuences
attributed to LMWH therapy in the treatment of cancer patients.r weight heparin; NFκB, nuclear
broblast growth factor; VEGF,
rtment of Biological Sciences,
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The association between increased tissue factor (TF) expression and
thrombotic complications in cancer is well established [1], and the
expression of TF by tumour cells is suggested to be an early event during
the onset of the disease [2]. High levels of TF activity have been shown
to increase the risk of thrombotic events in cancer patients [3–7] and in
particular, the release of TF as circulating microparticles is reported to
be an important link between cancer and thrombosis [8–12]. Heparin
treatment of cancer patients has been reported to be beneﬁcial in the
control of the hypercoagulable state [13]. In addition to the anticoagu-
lant effect, heparin-compounds have been associated with the reduc-
tion in the cellular procoagulant activity [14–16]. In particular, low
molecular weight heparin (LMWH) is thought to be effective in the
regulation of the procoagulant activity [17]. Similarly, we previouslyreported the reduction in levels of circulating TF in the plasma from
pancreatic cancer patients receiving prophylactic LMWH, compared to
those not receiving the treatment [18]. The majority of the data report-
ing the inﬂuence of LMWH treatment on TF expression has been ac-
quired from in vivo measurements carried out in cancer patients.
Therefore, due to the heterogeneous nature of the samples, any possible
speciﬁcity of the action of LMWH on downregulating TF expression is
undetermined. In order to examine the inﬂuence of LMWH in a homog-
enous population of cells, in this study we have investigated the inﬂu-
ence of LMWH on TF expression and activity in cancer cell lines from
ﬁve separate tissues; pancreatic, breast, colocarcinoma, ovarian and
melanoma. We have quantiﬁed the TF mRNA and protein, as well as
the surface TF activity in these cells. In addition, we have identiﬁed
the transcriptional activity and cellular localisation of nuclear factor-κB
(NFκB) as the likely mechanism by which LMWH downregulates TF
expression. The regulation of TF expression by NFκB has previously
been reported [19] and it is known that heparin exerts an anti-inﬂam-
matory inﬂuence on cells [20–24]. The mechanism by which LMWH
suppresses the transcriptional activity of NFκB is thought to involve
interference with the nuclear translocation of NFκB [22–24]. Finally,
by incubating the cell lines with a range of concentrations of epidermal
growth factor (EGF), basic ﬁbroblast growth factor (bFGF) and vascular
endothelial growth factor (VEGF) in the presence and absence of
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prevents the induction of TF expression, by suppressing the growth
factor receptor-mediated activation of NFκB.2. Material and methods
2.1. Cell culture
The pancreatic cell line BxPC-3 (LGC-ATCC, Teddington, UK) was
cultured in RPMI-1640 medium; MDA-MB-231 breast cancer cell line
was cultured in Leibovitz's L-15 medium; LoVo colocarcinoma cell line
was cultured in F-12K medium; SKOV-3 ovarian cancer cell line was
cultured in McCoy's 5a medium and A375 malignant melanoma cell
line was cultured in Dulbecco's Modiﬁed Eagle's medium. All prepara-
tions of media contained 10% (v/v) foetal calf serum (FCS) and 1%
(v/v) antibiotic/antimycotic solution. The expression and activity of TF
in these cells were conﬁrmed as described below. Cells were supple-
mented with a range of LMWH concentrations (Mr ~3000) (Sigma
Chemical Company Ltd, Poole, UK) containing approximately
56 units/mg of heparin activity and conﬁrmed using dalteparin at
equivalent activities (units/ml).2.2. Preparation of standard TF mRNA and measurement of TF mRNA
expression by quantitative real-time RT-PCR
To prepare a TFmRNA standard, full-length TF cDNAwas cloned into
the pT7T3-18 vector and used to express the target mRNA. The plasmid
was digested with Sac I (10 units, Promega Corporation, Southampton,
UK) at 37 °C for 1 h and the 3′-overhang was ﬁlled in with T4-DNA po-
lymerase (9.7 units/ml, Promega). TF mRNA was transcribed using the
MAXIscript®-T7T3 in vitro-transcription kit (Ambion/Applied Biosys-
tems, Warrington, UK). The DNA was then destroyed with DNase I
(2 units) and the mRNA precipitated and washed with 70% (v/v) etha-
nol. The mRNA sample was then reconstituted and the concentration
and purity of RNA established. The identity of the TF mRNA was
conﬁrmed by end-point RT-PCR prior to use. One-step end-point
RT-PCR was carried out using Ready-To-Go RT-PCR beads (Amersham
Pharmacia Biotech Inc, Giles, UK) and 100 ng of standard mRNA as
before [25]. The ampliﬁcation (30 cycles) was performed as follows:
1 min at 95 °C, 1 min at 60 °C, followed by 1 min at 72 °C. The primers
used were (TF-forward) 5′-ACCTGGAGACAAACCTCGGAC-3′ and (TF-
reverse) 5′-GAGTTCTCCTTCCAGCTCTGC-3′. Products were visualised
on a 1.5% (w/v) agarose gel.
Sets of cells (2×105/ml) were incubated with a range of LMWH
concentrations (0–2000 μg/ml) for 24 h. Total RNA was isolated using
the TRI-reagent system (Sigma) from 106 cells. Real-time RT-PCR was
carried out using primer sets designed to detect TF andβ-actin and opti-
mised by adhering to criteria for successful analysis [26]. Single-step
RT-PCR was carried out in triplicates using 100 ng of total RNA from
each sample tested. A set of previously prepared standard TF mRNA
ranging 0.05–10 ng was included. The reaction was carried out at an
annealing temperature of 60 °C using the PowerSYBR Green RNA-to-
CT 1-Step Kit (Applied Biosystems, Warrington, UK) on an iCycler
thermal cycler (Bio-Rad, Hemel Hempstead, UK) and the data analysed.
The primers used were:
TF-forward 5′-TACAGACAGCCCGGTAGAGTG-3′,
TF-reverse 5′-GAGTTCTCCTTCCAGCTCTGC-3′,
β-actin-forward 5′-TGATGGTGGGCATGGGTCAGA-3′,
β-actin-reverse 5′-GTCGTCCCAGTTGGTGACGAT-3′
Following the reaction, the data were adjusted relative to the
β-actin and then the exact TF mRNA quantities determined from the
standard curve prepared using the in vitro-transcribed TF mRNA.2.3. Measurement of total TF antigen, cell surface TF activity and
released-TF activity
Sets of cells (2×105/ml) were incubated with a range of LMWH
concentrations (0–2000 μg/ml) for 24 h and in some instances, with
200 μg/ml for up to 6 days. To measure the total cellular TF antigen
the cells were lysed in the presence of a protease inhibitor cocktail
(Active Motif) and 20 μg of the samples analysed using a TF-antigen
ELISA kit (Afﬁnity Biologicals, Ancaster, Canada) as described before
[27]. Microparticle-derived TF was measured by ELISA directly. The TF
concentrations were determined against a standard curve prepared
simultaneously using recombinant TF (0–200 ng/ml) (American Diag-
nostica Inc., Stamford, USA). Additionally, the TF activities on the cells
and released into the media were measured using a chromogenic
assay based on quantifying the activity of the generated thrombin, as
previously described [28].
2.4. Isolation of cell-derived microparticles and determination of
microparticle density
Microparticles were isolated from serum-free conditioned media
from each cell line by ultracentrifugation as described previously
[29,30]. Brieﬂy, the media were centrifuge in a microcentrifuge at
8000 rpm for 10 min to remove cell debris. The microparticles were
then sedimented by centrifuging at 100,000 g for 60 min at 20 °C. The
pellet was then resuspended in PBS and sedimented again and ﬁnally,
the pellet was resuspended in 100 μl of PBS. Microparticle density was
determined using the Zymuphen microparticle assay kit (Hyphen
BioMed, Quadratech, Epsom, UK) and equal amounts of microparticles
were then used to measure the TF content as described above.
2.5. Cell transfection and quantiﬁcation of NFκB activity and measurement
of nuclear translocation of NFκB
Cells (5×105/well) pre-adapted to OptiMEM-1 media, were trans-
fected with the Pathdetect pNFκB-Luc plasmid (1 μg, Stratagene, Cam-
bridge, UK) using Lipofectin according to the manufacturer's
instructions. The cells were then incubated with a range of LMWH
concentrations (0–2000 μg/ml) for 24 h prior to measuring the lucifer-
ase activity as previously described [25,31]. Additionally, a set of
untransfected cells was treated for 24 h with the NFκB inhibitor, pyrro-
lidinedithiocarbamate ammonium (Tocris Bioscience, Bristol, UK)
(10 μM) prior to measuring TF antigen expression, as before [25]. In
order to measure the nuclear localisation of NFκB, sets of cell lines
were incubated for 24 h in the presence of LMWH (200 μg/ml) together
with an untreated sample, a sample treated with pyrrolidinedithiocar-
bamate ammonium and a sample treated with betulinic acid
(1.04 μM) to activate NFκB (30 min). Cellular nuclei were prepared
from the samples using the Nuclear Extract Kit (Active Motif, Rixensart,
Belgium), and lysed in cell lysis buffer (Active Motif) containing prote-
ase inhibitors. The concentration of the total protein was determined
using Bradford protein estimation reagent (Sigma). The samples were
then diluted 1:1 (v/v) with 2× Laemmli's sample buffer and similar
quantities of protein were separated by 12% (w/v) SDS-PAGE electro-
phoresis. The proteins were then transferred onto nitrocellulose over-
night, blocked in TBST buffer (Tris–HCl (20 mM) pH 8.0, 150 mM
NaCl, Tween 20 (0.05% w/v)) and probed with a polyclonal anti-
human NFκB-p65 antibody (eBioscience, Hatﬁeld, UK) diluted 1:2000
(v/v) in TBST buffer, washed and probed with a goat anti-rabbit HRP-
conjugated antibody (Santa Cruz Biotechnology) diluted 1:1000 (v/v)
and developed using stabilised 3,3,′5,5 Tetramethylbenzidine (TMB)-
stabilised substrate (Promega Corporation). Visible bands were
recorded using the GeneSnap Program (SynGene). In addition, sets of
cells were treated as above but were ﬁxedwith 3% (v/v) glutaraldehyde
for 15 min and then washed with PBS. The cells were permeabilised
using 0.2% (v/v) Triton X-100 for 15 min and blocked with 10% (w/v)
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Fig. 1. Analysis of the inﬂuence of LMWH on the expression of TF mRNA. Sets of cells (2×105) were incubated with a range of LMWH concentrations (0–2000 μg/ml) for 24 h (A) or
with LMWH (200 μg/ml) for up to 6 days (B). Total RNA was isolated from the cells and analysed for TF expression by real-time quantitative RT-PCR. The data were normalised
against β-actin mRNA in each sample and the quantity of RNA determined from a standard curve prepared by ampliﬁcation of in vitro-transcribed TF mRNA. Data represent the
mean of 3 experiments measured in triplicates (*=pb0.05 vs. respective untreated sample).
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human p65 antibody was diluted 1:500 in PBS containing 1% (w/v) BSA
and cells incubated with the antibody solution for 1 h. The cells were
then washed three times with PBS. A goat anti-rabbit FITC-conjugated
antibodywas diluted 1:500 in PBS containing 1% (w/v) BSA and incubat-
ed with the cells for 1 h. The cells were washed four times with PBS and
the slidemounted inmountingmedia containingDAPI. Imageswere ac-
quired using ﬂuorescence imaging microscopy and captured using
MetaVue software.
2.6. Inﬂuence of the supplementation of cells with EGF, bFGF or VEGF on the
downregulation of TF by LMWH
Each cell line (2×105/ml of media) was supplemented with a range
of concentrations of either EGF (0–10 ng/ml), bFGF (0–20 ng/ml)
(Sigma Chemical Company Ltd.) or VEGF (0–4 ng/ml) (TCS Cellworks,Buckingham, UK) in the presence or absence of LMWH (200 μg/ml).
The cells were incubated for 24 h and the amount of TF antigen deter-
mined by ELISA, as above.
2.7. Statistical analysis
Unless otherwise stated, all values presented are the mean value
from the number of experiments stated, togetherwith the derived stan-
dard error of mean. Statistical analysis was carried out using the Statis-
tical Package for the Social Sciences (SPSS Inc. Chicago, USA). One-Way
ANOVA procedure was used for the analysis of variance of data.
3. Results
Prior to the study, the expression of TF in all ﬁve cell lines was
conﬁrmed and the cells were shown to exhibit a signiﬁcant amount of
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Fig. 2. Analysis of the inﬂuence of LMWH on the expression of TF antigen. Sets of cells (2×105) were incubated with a range of LMWH concentrations (0–2000 μg/ml) for 24 h (A) or
with LMWH (200 μg/ml) for up to 6 days (B). The cells were then lysed and analysed by ELISA and TF concentrations determined from a standard curve prepared with recombinant
TF alongside. Data represent the average of 4 experiments measured in duplicates (*=pb0.05 vs. respective untreated sample).
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samples within the sections below). No signiﬁcant change in level of
apoptosis was detected in any of the LMWH-treated cells, compared
to untreated cells.
3.1. Inﬂuence of LMWH on cellular TF expression and activity
At an optimal primer concentration of 100 nM, the real-time PCR
efﬁciency was consistently greater than 83%. Furthermore, the ampliﬁ-
cation of the standard TFmRNAwas linear over the range of 0.05–10 ng
with a correlation coefﬁcient of 0.989 and therefore minimum sensitiv-
ity of the reaction was assumed to be 0.05 ng of TF mRNA. The basal
expression of TF mRNA was highest in LoVo cells (10.7±3.0 ng/106
cells), lower in BxPC-3 (7.9±1.0 ng/106 cells), MDA-MB-231
(8.6±2.8 ng/106 cells) and A375 cells (8.6±0.3 ng/106 cells) and
lowest in SKOV-3 cells (7.7±0.1 ng/106 cells). Incubation of BxPC-3,
LoVo and MDA-MB-231 cells for 24 h, with 20 μg/ml, or higher concen-
trations of LMWH resulted in the suppression of TF mRNA expression
(Fig. 1A). In addition, the downregulation of TF mRNA expression wasachievable with 200 μg/ml of LMWH in A375 and SKOV-3 cells. The
expression of TF mRNA decreased at different rates in the ﬁve cell
lines on incubation with LMWH (200 μg/ml) (Fig. 1B) but remained
unaltered in untreated cells (not shown) adjusted to cell numbers.
Incubation of BxPC-3, LoVo and A375 cells with LMWH resulted in
the reduction in detectable total TF antigen which was achievable at
differing LMWH concentrations. However, the level of TF antigen
did not drop below 60% of the untreated control in any of these cell
lines (Fig. 2). In contrast, cellular TF decreased rapidly at high concen-
trations of LMWH (200–2000 μg/ml) in MDA-MB-231 and SKOV-3
cells, diminishing to approximately 21% of the untreated control.
Moreover, prolonged incubation of BxPC-3, LoVo and A375 cells
with LMWH (200 μg/ml) suppressed the expression of TF protein
over the 6 days (Fig. 2B) but remained unaltered in untreated cells
(not shown) adjusted to cell numbers. In addition to the total TF
antigen, incubation of all cells with LMWH resulted in the reduction
in detectable cell surface TF activity, achievable at differing LMWH
concentrations (Fig. 3A). The reduction in TF activity was also time-
dependent (Fig. 3B) but remained unaltered in untreated cells
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Fig. 3. Analysis of the inﬂuence of LMWH on TF activity. Sets of cells (2×105) were incubated with a range of LMWH concentrations (0–2000 μg/ml) for 24 h (A) or with LMWH
(200 μg/ml) for up to 6 days (B). The cells were then resuspended in PBS and TF activity in samples (20 μl) measured using a chromogenic assay. The absorption values were then
converted into equivalent concentrations from a standard curve. Data represent the average of 3 experiments measured in duplicates (*=pb0.05 vs. respective untreated sample).
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antibody (American Diagnostica Inc) resulted in no detectable chro-
mogenic activity conﬁrming the TF activity on the cells surface
(not shown). Finally, the concentration of released TF into the condi-
tioned media of the untreated samples remained unaltered on treat-
ment with LMWH (0–2000 μg/ml) in all cell lines tested (Fig. 4A). In
contrast, continuous incubation of cells with LMWH (200 μg/ml)
resulted in progressive decrease in microparticle-derived TF
(Fig. 4B) which approximated the pattern of surface-TF activity
(Fig. 3B). The rate of release of microparticles was not signiﬁcantly
altered by any of the treatments and no additional TF antigen was
detectable in microparticle-depleted conditioned media.
3.2. Inﬂuence of LMWH on NFκB transcriptional activity and nuclear
translocation of NFκB
The Pathdetect-cis luciferase reporting system was optimised as
previously described [25,31]. This is a quantitative technique that
measures the transcriptional activity of NFκB taking into accountinﬂuences from other signalling mechanisms which can interfere
with the translocation of NFκB into the nucleus. Incubation of cells
with a range of LMWH concentrations (0–2000 μg/ml) resulted in
the dose-dependent suppression of basal NFκB activity in BxPC-3
and MDA-MB-231 cells (Fig. 5). LMWH was also effective in suppres-
sion of basal NFκB activity in LoVo and SKOV-3, and in A375 cells at
the higher concentrations (200–2000 μg/ml). Furthermore, incuba-
tion of all the tested cells with the NFκB inhibitor pyrrolidinedithiocar-
bamate ammonium (10 μM) resulted in decreases in TF antigen
expression (Fig. 6A) that were comparable to inhibition levels
achieved with LMWH (Fig. 2). Finally, inclusion of betulinic acid
(1.04 μM) to activate NFκB, reversed the suppression of TF antigen
expression by LMWH (200 μg/ml) (Fig. 6B). This data was consistent
with the suppression of the nuclear translocation of NFκB upon treat-
ment of cells with LMWH (200 μg/ml) which was comparable but
lower than inhibition with pyrrolidinedithiocarbamate ammonium
(Fig. 6C and Supplemental Fig. I show MDA-MB-231 cells). Further-
more, the level of nuclear NFκB in untreated cells was comparable to
that induced by incubation with betulinic acid.
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Fig. 4. Analysis of inﬂuence of LMWH on released TF antigen. Sets of cells (2×105) were incubated with a range of LMWH concentrations (0–2000 μg/ml) for 24 h (A) or with LMWH
(200 μg/ml) for up to 6 days (B). The media from the cells was then collected and the microparticles isolated by ultracentrifugation. The microparticle density was then measured and
the TF concentration in equal amounts of microparticles was determined. Data represent the average of 4 experiments measured in duplicates (*=pb0.05 vs. respective
untreated sample).
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the downregulation of TF expression by LMWH
Incubation of all cell lines with EGF (2.5–10 ng/ml) resulted in
dose-dependent increases in TF expression, with the greatest in-
creases observed in LoVo, SKOV-3 and A375 cells (supplemental
Fig II). Furthermore, inclusion of LMWH (200 μg/ml) signiﬁcantly
reduced the TF expression in response to EGF in BxPC-3, MDA-MB-
231 and SKOV-3 cells, but was partially counteracted on incubation
with higher concentrations of EGF in LoVo, MDA-MB-231, SKOV-3
and A375 cells (Fig. 7). Supplementation of cells with bFGF
(5–20 ng/ml) also resulted in dissimilar increases in TF expression in
BxPC-3, SKOV-3 and A375 cells (Supplemental Fig II). Furthermore,
inclusion of LMWH (200 μg/ml) resulted in the reduction in TF expres-
sion in all cell lines but was counteracted by increasing concentrations
of bFGF in BxPc-3, MDA-MB-231 and SKOV-3 cells. Finally, incubation
with VEGF (1–4 ng/ml) resulted in large increases in the expression ofTF in SKOV-3 and A375 cells (Supplemental Fig II), whilst the inclusion
of LMWH (200 μg/ml) resulted in decreases in TF expression which
were counteracted to differing extents at higher concentrations of
VEGF in all cell lines (Fig. 7).
4. Discussion
It has previously been reported that treatment of patients with
LMWH has beneﬁcial inﬂuences beyond that of the immediate antico-
agulant effect, through suppressing TF expression [17,18,32–35]. In
these experiments, we explored the underlying mechanism by which
LMWH suppresses TF expression in cancer cells. We have shown that
incubation of cells with LMWH (20–2000 μg/ml) resulted in the
suppression of TF mRNA expression, but became effective at various
concentrations of LMWH in the different cell lines tested (Fig. 1). The
suppression of TF mRNA expression was also time-dependent affecting
the cells at different intervals. Downregulation ofmRNA expressionwas
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Fig. 5. Analysis of the inﬂuence of LMWH on the transcriptional activity of NFκB. Sets of cells were transfected with the pNFκB-Luc plasmid, incubated with a range of LMWH con-
centrations (0–2000 μg/ml) for 24 h, lysed and luciferase activity measured. Data represent the average of 3 experiments measured in duplicates (*=pb0.05 vs. respective
untreated sample).
1597C. Ettelaie et al. / Biochimica et Biophysica Acta 1812 (2011) 1591–1600concurrent with the suppression of the transcriptional activity and
nuclear translocation of NFκB by LMWH at approximately the same
effective concentrations in all cell lines tested (Fig. 5 and MDA-MB-
231 cell shown in Fig. 6C and Supplemental Fig. I). However, NFκB
was affected to a greater extent by LMWH in BxPC-3 and MDA-MB-
231 cell lines than TF mRNA levels. It is known that in addition to the
NFκB promoter region, the TF mRNA may also be transcribed through
AP1, SP1 and EGR1 promoter sites [19]. Therefore, whilst the transcrip-
tional activation of NFκB generates a large proportion of expressed TF
mRNA in these cells, we cannot rule out additional contribution from
the other promoters in these two cell lines. Consequently, although
the NFκB activity is suppressed by incubation of cells with LMWH, the
expression of TF mRNA is not attenuated proportionally due to the ac-
tivity of other enhancer proteins. The function of NFκB in the regulation
of TF expression in all cells was conﬁrmed by the inhibition of NFκB
using an inhibitor whilst the involvement of NFκB in the mechanismof inhibition by LMWH was demonstrated using the NFκB activator
betulinic acid (Fig. 6). Although betulinic acids are also known to induce
apoptosis in tumour cells, the concentrations used by us (1.04 μM)were
far lower than those reported to induce apoptosis (15–80 μM) [36–38]
and no cell apoptosis was detected in our experiments.
Decreases in both TF antigen and TF activity levels on incubation
with LMWH were not to the same extent as the reductions in TF
mRNA levels. Decreases in TF antigen levelled off at above 60% of the
untreated control in BxPC-3, LoVo and A375 cells (Fig. 2) on incubation
with high concentrations of LMWH (2000 μg/ml), suggesting the pres-
ence of a reservoir of intracellular TF that is not immediately depleted
on suppression of TF mRNA expression. This is in agreement with the
concept that TF exists in various pools within cells [39,40]. Moreover,
the moderate decrease in total TF antigen in these cells was reﬂected
in cell-surface TF activity which decreased to 72%, 55% and 65% of the
untreated control in BxPC-3, LoVo and A375 cells respectively
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remained constant on incubation with LMWH (Fig. 4A). In contrast,
the level of TF antigen, and to a lesser extent TF activity, in MDA-MB-
231 and SKOV-3 cells was reduced signiﬁcantly on incubation with
LMWH suggesting that the majority of the remaining cellular TF was
present at the surface of these cells. Therefore, it may be hypothesised
that MDA-MB-231 and SKOV-3 cells readily transfer and release TF
into the media. In contrast, BxPC-3, LoVo and A375 cells may retain a
higher proportion of TF within intracellular reservoirs. This mechanism
explains the presence of high TF antigen levels in LoVo cells, despite the
rapid decrease in TFmRNA. Furthermore, the rapid release of TF also ex-
plains the large reductions in TF antigen in SKOV-3 cells despitemodest
downregulation of TF mRNA, in response to LMWH. A previous study
showed no effect of LMWH on tumour TF activity in mouse xenograft
model of cancer [14]. However, in this model, LMWHwas administered
as a single bolus injection prior to the injection of the tumour cells into
the animals. In our study, the time-course of the downregulation of TF
antigen and activity in BxPC-3, LoVo and A375 cell lines indicates thattreatment of these cell lines with LMWH (200 μg/ml) resulted in the
progressive downregulation of TF antigen expression (Fig. 2B) and
release of TF (Fig. 4B) over 6 days and was cumulative over the period
of testing. The gradual reduction of cellular and released TF antigen
further supports the presence of intracellular reservoirs of TF that
replenish the surface TF. It is also noteworthy that the rate of micropar-
ticle release was independent of that of TF release and did not signiﬁ-
cantly alter during the period of testing. It is therefore possible that
prolonged treatment with LMWH would be required for any effective
long term control of TF-mediated hypercoagulable state. In this work,
wewere unable to sustain the cells for longer durations due to excessive
cell proliferation. However, these data are in agreementwith our previ-
ous clinical observations in pancreatic cancer patients indicating that
prophylactic treatmentwith dalteparinmay reduce the level of circulat-
ing TF antigen in the plasma of patients compared to those not receiving
LMWH [18]. Consequently, our data indicate that therapeutic levels of
LMWH, comparable to 20–200 μg/ml of the LMWH used here (activi-
ty=0.1–1 units/ml) may be effective in reducing the risk of recurrent
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Fig. 7. Analysis of the inﬂuence of EGF, bFGF and VEGF on the downregulation of TF by
LMWH. Sets of cells (2×105) were incubated with a range of concentrations of EGF
(0–10 ng/ml), bFGF (0–20 ng/ml) or VEGF (0–4 ng/ml) in the presence or absence of
LMWH (200 μg/ml) for 24 h. The cells were then lysed and analysed by ELISA and TF
concentrations were determined from a standard curve prepared alongside. Percentage
reduction in TF antigen was determined against samples containing the same concentra-
tions of growth factor but devoid of LMWH. Data represent the average of 3 experiments
measured in duplicates. *=pb0.05 for the alteration in the level of TF suppression against
the respective sample, without growth factor.
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carried out using LMWH obtained from Sigma Chemical Company Ltd,
and conﬁrmed using dalteparin. Therefore, one also has to take into
consideration that different LMWH preparations used as pharmacolog-
ical agents are likely to have varying anti-neoplastic properties [41]
attributed to the varying length of fractionated heparin chains in these
preparations, stemming from different methods of production. There-
fore, clinical doses relevant for ‘secondary prophylaxis’ would have to
be used in a twice daily schedule to achieve sustained levels of anticoag-
ulant activity of 0.5–1.5 units/ml (3500–10,500 units for a 70 kg aver-
age adult). In fact multiple daily doses of 5000 units have been
reported in the prophylactic treatment of cancer patients [42,43] and
dalteparin dosages of 2500–18,000 units have been cited in protocols.
These values are comparable to the concentrations used in this study
(200 μg/ml=approximating 1 unit/ml) and therefore it is likely that
attenuation of TF expression is realistic at these therapeutic doses.In order to examine the hypothesis that LMWH downregulates TF
expression through interfering with growth factor receptor signalling
and subsequent suppression of basal NFκB transcriptional activity, we
measured the effectiveness of LMWH (200 μg/ml) in suppressing TF
expression in the presence of increasing concentrations of the growth
factors EGF, bFGF and VEGF. The engagement of growth factors with
their receptors is known to induce NFκB activity [44] through parallel
signalling pathways including the mitogen activated protein kinase
pathway [45]. Furthermore, the increased expression of growth factor
receptors is known to be an underlying cause of the hyperactivity of
cancer cells to growth factors [46,47]. Our data suggest that LMWH
may interfere with the interaction of the growth factors tested here
(and possibly others) with their respective cell surface receptors. The
interaction of heparin with bFGF and VEGF but not EGF is well docu-
mented. Therefore, one possible explanation for the observed decrease
in the TF expressionmay involve interferencewith the action of heparin
binding-EGF component co-puriﬁed with the isolated EGF preparation.
In addition, increasing concentrations of growth factors partially
reduced the effectiveness of LMWH in reducing TF expression (Fig. 7).
Furthermore, the cell lines used in this study exhibited distinctive
sensitivities to growth factors and therefore, were affected by LMWH
to different extents. In particular, the expressions of TF in LoVo and
A375 cells were neither signiﬁcantly inﬂuenced on supplementation
with the lower concentrations of LMWH(Fig. 1A), norwere they greatly
reversed by the inclusion of growth factors (Fig. 7). This in turn may be
indicative of a functional mutation in the growth factor receptors or
associated proteins as discussed previously [48], rendering these hyper-
responsive and therefore, less subject to normal cellular regulation.
5. Conclusions
The beneﬁts of LMWH in the treatment of cancer patients have
previously been reported [49]. Moreover, the beneﬁcial effects of anti-
coagulants in cancer patients do not appear to be due to any direct anti-
tumour effects and have been attributed to the suppression of the
release of circulating TF [50]. Data obtained from this investigation sug-
gest that LMWH is capable of downregulating the expression of TF
mRNA through a mechanismwhich appears to involve the suppression
of the transcriptional activity of NFκB and subsequently results in the
gradual reduction of the intracellular TF reservoir. Since this stored TF
can replenish the active cell-surface TF, the eventual depletion of the
reserves would result in the lower levels of procoagulant cellular TF,
and released TF-containing microparticles by the tumour cells. There-
fore, the beneﬁts of LMWH therapy may extend beyond the immediate
inhibition of coagulation and sustained therapymay be advantageous in
limiting the expression of TF.
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